Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nuvo Pharmaceuticals Inc MRVFF

Healthcare Drug Manufacturers - Specialty & Generic
Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. see more

Recent & Breaking News (OTCQX:MRVFF)

Nuvo Research® settles litigation with Mallinckrodt Pharmaceuticals

Canada NewsWire September 8, 2014

Nuvo Research® to Present at Rodman & Renshaw 16th Annual Global Investment Conference

Canada NewsWire September 4, 2014

Nuvo Research® Completes Enrolment in WF10(TM) Phase 2 Clinical Trial

Canada NewsWire September 3, 2014

Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014

Business Wire August 11, 2014

Nuvo Research® announces 2014 second quarter results

Canada NewsWire July 30, 2014

IGI Laboratories, Inc. Announces Joint Stipulation

PR Newswire June 26, 2014

Nuvo Research to present at Bloom Burton & Co Healthcare Investor Conference

Canada NewsWire June 17, 2014

Nuvo Research announces director election results of its annual general meeting

Canada NewsWire June 11, 2014

Nuvo Research® announces U.S. FDA approval of third-party generic of PENNSAID 1.5%

Canada NewsWire May 29, 2014

Nuvo Research® announces 2014 first quarter results

Canada NewsWire April 30, 2014

Nuvo Research (T.NRI) enters collaboration to develop topical dermatology products

Stockhouse Editorial April 23, 2014

Nuvo Research Announces Collaboration to Develop Topical Dermatology Products

Canada NewsWire April 23, 2014

Nuvo Research® closes $3.1 million private placement

Canada NewsWire April 1, 2014

Nuvo Research announces 2013 fourth quarter & year-end results

Canada NewsWire February 20, 2014

Nuvo Research (T.NRI) gains 5% on US commercial launch of PENNSAID(R) 2%

Gaalen Engen February 10, 2014

Nuvo Research Announces the U.S. Commercial Launch of PENNSAID® 2% by Mallinckrodt

Canada NewsWire February 10, 2014

Nuvo Research Announces FDA Approval of PENNSAID® 2%

Canada NewsWire January 17, 2014

Nuvo Research® and NovaMedica Sign Agreement to Market Pennsaid® in Russia

Business Wire December 19, 2013

Nuvo Research® and NovaMedica sign agreement to market Pennsaid® in Russia

Canada NewsWire December 19, 2013

Nuvo Research® to Receive US$2.0 Million

Canada NewsWire October 10, 2013